

We are looking at D₂ and 5HT_{2A} receptor binding and beyond in the development of treatments for schizophrenia



Sepracor Inc., the North American subsidiary of Dainippon Sumitomo Pharma Co., Ltd., is committed to ongoing research and development in schizophrenia. Sepracor is looking beyond receptor binding to learn more about this deeply complex disorder.

There is no one single cause for the many symptoms of schizophrenia, which is influenced by different genetic, environmental, developmental, and other factors. Research has shown that the pathology of schizophrenia is complex and may be associated with more than one receptor site and neurotransmitter in the brain.¹



Researching the relationship between receptor binding and the pathophysiology of schizophrenia may help researchers better understand how patients are affected. At Sepracor, our goal is to gain new insights into this devastating illness to improve patient outcomes.

Reference: 1. Kim DH, Maneen MJ, Stahl SM. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimension of schizophrenia. *Neurotherapeutics*. 2009;6:78-85.



DAINIPPON
SUMITOMO
PHARMA



SEPRACOR

BOSTON

62nd Institute on Psychiatric Service
Leadership in Discovery and Service: 21st Century Psychiatry

October 14-17, 2010

REGISTER EARLY!



Cosponsored by
Drexel University College of Medicine/
Behavioral Healthcare Education

photos: Bartek Wisk



APA's Leading Educational
Conference on Public and
Community Psychiatry
American Psychiatric Association

Conference Highlights, Advance Registration,
Hotel and Travel Information are available at:

www.psych.org/ips

For questions, please call 1-888-357-7924
(toll free) or call 703-907-7300.

The American Psychiatric Association's leading educational conference on clinical issues and
community mental health helps meet the service needs of people with severe mental illness.

JERALD KAY • ALLAN TASMAN • AARON T. BECK • JAMES
F.T. BUGENTAL • GLEN O. GABBARD • JAY HALEY • OTTO
KERNBERG • PETER D. KRAMER • TRACEY EELLS • ROBERT
D. STOLOROW • GEORGE E. VAILLANT • IRVIN YALOM •
E. JAMES ANTHONY • RICHARD D. CHESSICK • ROBERT
COLES • HOWARD C. CUTLER • HABIB DAVANLOO • PAUL
JOHN MARKOWITZ • WILLIAM N. GOLDSTEIN • PAUL A. DEWALD • ROBERT LANGS • PAUL CRITS-CHRISTOPH • TRACY
ARNOLD M. LUDWIG • JOHN NORCROSS • IRVIN YALOM • E. JAMES ANTHONY • RICHARD D. CHESSICK • ROBERT COLES
MENNINGER • JOEL YAGER • JOHN NORCROSS • IRVIN YALOM • E. JAMES ANTHONY • RICHARD D. CHESSICK • ROBERT COLES
SPECTOR PERSON • T. BECK • JAMES F.T. BUGENTAL • GLEN O. GABBARD • JAY HALEY • OTTO KERNBERG • PETER D. KRAMER • TRACEY EELLS • ROBERT D. STOLOROW • GEORGE E. VAILLANT • IRVIN YALOM • E. JAMES ANTHONY • RICHARD D. CHESSICK • ROBERT COLES • HOWARD C. CUTLER • HABIB DAVANLOO • PAUL A. DEWALD • ROBERT LANGS • PAUL CRITS-CHRISTOPH • TRACY
T. Byram Karasu, Editor-in Chief
Highlights:
Therapist Interventions in the Interpersonal
and Cognitive Therapy Sessions of the
Treatment of Depression Collaborative
Program
M.B. Connolly, Gibbons, Ph.D.,
P. Crits-Christoph, Ph.D., et al
Reflections on Gifts in the Therapeutic Setting:
The Gift from the Patient to the Therapist
Andrew I. Smolar, M.D.
Dedicated to the
Trans-theoretical Research & Practice of Psychotherapy
Official Journal of the AAP Founded in 1939

Incorporating the *Journal of Psychotherapy Practice and Research*
Published four times per annum: *American Journal of Psychotherapy*
Belfer Center, Room 405 • 1300 Morris Park Avenue • Bronx, NY 10461
Telephone: (718) 430-3503, FAX: (718) 430-8907
E-mail: info@ajpp.org; Web site: www.ajpp.org

Candidates and Employers Connect through the APA Job Bank

psych.org/jobbank



Candidates

- Search the most comprehensive online listing of psychiatric positions at psych.org/jobbank.
- Register to post your resume, receive instant job alerts, use the career tools and more.
- Visit the redesigned and enhanced APA Job Bank website to find the ideal position!

Employers

- Use the many resources of the APA Job Bank to meet qualified candidates and make a smart recruitment decision.
- Advertise in the *Psychiatric News* or *Psychiatric Services* classifieds and the APA Job Bank and receive a 10% discount on each.

For more information, contact Lindsey Fox
at 703-907-7331 or classads@psych.org



The NEW www.appi.org makes its debut! *Visit today*

The new www.appi.org offers:

- Special Discounts for American Psychiatric Association Members and Members-in-Training
- Detailed descriptions on more than 700 titles plus subscription products
- **My Account** history with order and tracking information
- Fast and easy navigation
- Enhanced search engine

The screenshot shows the homepage of the American Psychiatric Publishing website. At the top left is the logo for American Psychiatric Publishing, Inc. The navigation bar includes links for Disorders, Subjects, Assessment & Treatment, Guides, References & Manuals, Books, Journals, and eContent. A search bar is prominently displayed with a 'Go' button and a link to 'Advanced Search'. Below the search bar, there are several featured sections: 'Featured Titles' with a book cover for 'Long-Term Psychodynamic Psychotherapy' by Glen O. Gabbard, M.D., priced at \$65.00; 'psychiatryonline.com' offering online access to psychiatric resources; 'Featured Author' for Glen O. Gabbard, M.D.; 'Explore the DSM Library' featuring the 'DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS, FOURTH EDITION, TEXT REVISION, DSM-IV-TR'; and 'Discover the Journals of American Psychiatric Publishing' showing covers for 'PSYCHIATRIC SERVICES' and 'FOCUS'. On the right side, there are sections for 'Resources' (listing various user groups like APA Members, Educators, etc.), 'Search Books' (powered by Google), and 'Subscribe' (to the APPI Newsletter). The footer contains copyright information and contact details.

Special Discount for Members:
15% Discount for APA Members
30% Discount for APA Members-in-Training



The First and Last Word in Psychiatry

American Psychiatric Publishing, Inc.
appi@psych.org • 1-800-368-5777 • 703-907-7322

A culture like no other



At **Greenwich Hospital**, a 174-bed regional provider of care and affiliate of Yale New Haven Health, you'll find a hospital and a working culture like no other. Conveniently located minutes from I-95, I-684, I-287, the Merritt/Hutchinson Parkway and Westchester County—and close to public transportation and shuttle service—Greenwich Hospital offers a beautiful, state-of-the-art facility that serves as a national model for advanced health care design.

Psychiatrist

Full-Time

In this role, you will be providing diagnostic assessment and psychiatric treatment to individuals who present themselves to the Outpatient Psychiatric Treatment Center, Hospital Emergency Room or Inpatient Unit with symptoms of mental illness or emotional distress. Must be MD Board Certified in Psychiatry with outpatient experience. Bilingual or experience with a geriatric or adolescent population is a plus.

Greenwich Hospital offers a unique and rewarding environment, along with competitive compensation, generous benefits and extensive opportunities for growth. **Please apply online at www.greenwichhospitalcareers.com.** EOE.



www.greenwichhospitalcareers.com

betterhere.ca

Life's better here



Wanted: Psychiatrists who believe in balance *Freedom and tranquility at your doorstep.*

You've worked hard.
Made sacrifices.
Earned a lifestyle that offers rewarding work and unlimited recreation.

Here in the Southern Interior of British Columbia, Canada, we don't talk about work/life balance. We live it.

We are looking for Child and Adult Psychiatrists in many BC Southern Interior communities. Psychiatrists are eligible for competitive recruitment and retention allowances as well as generous on-call packages.

What are you waiting for?

Life's better here. Visit www.betterhere.ca to find out why.

British Columbia, Canada



1-877-522-9722 physicianrecruitment@interiorhealth.ca



IOM International Organization for Migration
OIM Organisation Internationale pour les Migrations
OIM Organización Internacional para las Migraciones

PSYCHIATRIST (Bangkok, Thailand) – P3 level

The International Organization for Migration (IOM) in Thailand is looking for a Psychiatrist who will evaluate patients referred by panel physicians or others, for possible psychiatric conditions, including major and minor psychiatry, mental deficiencies and brain damage and substance abuse problems, provide opinion on diagnosis and classification and a comprehensive report on behalf of the Resettlement Health Assessment Programmes.

Qualifications and Core Competencies: University degree in Medicine with specialization in psychiatry. Five years work experience as a psychiatrist; working experience in general medicine practice as well as background in inter-cultural or ethno-medicine an advantage. Working experience with international organizations, non-governmental or governmental institutions/ organization with a multi-cultural setting and understanding of local conditions and refugees' needs an advantage. Excellent writing, communication and negotiation skills; ability to write reports concisely. Strong analytical skills. Good basic knowledge of neurology and child psychiatry. Demonstrated gender awareness and gender sensitivity. Personal commitment, drive for results, flexibility and efficiency. High level of integrity, sensitivity to confidentiality, cultural and social issues. Ability to work effectively and harmoniously with colleagues from varied cultures and professional backgrounds; team-work oriented with capacity to work independently. Good level of computer literacy. Ability and willingness to work in difficult conditions with frequent travel. Fluency in the English language is essential.

Salary: IOM offers an attractive salary package based on the United Nations System at P3 level.

Full terms of reference are available at the IOM website: www.iom.int. Deadline for submitting applications is 31 July 2010. Candidates should submit their applications at <http://www.iom.int/jahia/Jahia/pid/165>. The successful candidate will be requested to start as soon as possible.

SCENIC CALIFORNIA CENTRAL COAST
ATASCADERO STATE HOSPITAL
BE/BC Psychiatrist

Atascadero State Hospital now pays board certified psychiatrists starting at \$223,464 and advancing stepwise to \$255,732. Atascadero is the nation's premier center for the treatment of forensically committed mentally ill patients. Our hospital is a teaching site affiliated with the University of California, accredited by JCAHO, and recipient of the prestigious Codman Award. All of our psychiatrists are board eligible and most are board certified. Many of our psychiatrists have forensic subspecialty boards.

We are located midway between San Francisco and Los Angeles on the scenic central California Coast, south of Big Sur. We offer a spectacularly beautiful environment in San Luis Obispo County with temperate climate, beaches, world class wineries, cultural activities, golfing, sailing, riding, clean air, and excellent schools through the University level.

Our benefit package is valued at an additional 39%, which includes retirement plans (including safety retirement), health plans, professional liability coverage, paid holidays, educational leave, and generous annual leave. On-call duty is compensated hour for hour over and above the base salary. Applicants must hold a current California license, or have pending application with the Medical Board of California.

For a prompt and confidential review, send CV to:

Jeanne Garcia, M.D.
P. O. Box 7001
Atascadero, CA 93423-7001
(805) 468-2005 or fax (805) 468-2138
or e-mail us: jeanne.garcia@ash.dmh.ca.gov

WE ARE AN EQUAL OPPORTUNITY EMPLOYER.

ADULT PSYCHIATRY
Logan, Utah

One BC/BE adult psychiatrist is needed to join a partner who is employed by Intermountain Healthcare at Logan Regional Hospital. Position will be 30+ hours per week in an outpatient setting. Physician will also assist in coverage of inpatient services. Salary guarantee with transition to production. Signing bonus available. Full Intermountain benefits including defined pension and match in 401k. Moving allowance provided. EOE. Intermountain is frequently referenced nationally as one of the leaders in delivering high quality/low cost health care.

Logan is a beautiful university community of over 100,000. It is one of the top ten safest communities in which to live. Excellent primary care is available as well as a wide variety of specialty care. Logan fosters a wide variety of cultural, educational, recreational, sporting, commercial and health care opportune-ties. A moderate four seasons and majestic mountains allow for outstanding outdoor recreation opportunities. Along with the academic stimulation of Utah State University, Logan offers superb family living with quality school systems and reasonable living costs generally 10 to 25% less than other areas of the country.

Send/e-mail/fax CV to Intermountain Healthcare, Attn: Wilf Rudert, Physician Recruiting Dept., 36 S. State Street, 21st Floor, Salt Lake City, UT 84111. 800-888-3134. Fax: 801-442-2999. PhysicianRecruit@imail.org <http://intermountain.net/docjobs>

Associate Program Director

Cognitive Aging and Memory Clinical Translational Research Program (CAM-CTRP)

Institute on Aging, College of Medicine

University of Florida in Gainesville

The University of Florida (UF), College of Medicine, and Institute on Aging seek candidates for the tenure accruing position of Associate Program Director and Assistant, Associate or full Professor of the newly established Cognitive Aging and Memory Clinical Translational Research Program (CAM-CTRP). The position offers a highly dynamic and collaborative academic environment, an attractive benefits package, competitive salary, and outstanding resources.

Additional information is available by emailing cpascu@aging.ufl.edu.

QUALIFICATIONS

Candidates must possess a MD or MD/PhD and must have experience in cognitive aging/memory related clinical and interdisciplinary research funded by the NIH or other peer-reviewed funding. Other personal characteristics: an outstanding communicator; a collaborator, team player and problem-solver; a commitment to succeed; previous successful leadership role; the highest personal integrity and ethics.

POSITION SUMMARY

The primary goal of the CAM-CTRP is to develop a highly competitive cutting-edge interdisciplinary clinical translational research program, which translates basic science discoveries regarding cognitive aging and memory into clinical applications to slow, avert or restore the age-related cognitive decline and memory loss.

The incumbent will assist with leading the CAM-CTRP, including supervision of junior investigators, trainees and staff; will assist in developing a translational research program in the area of cognitive aging and memory; will promote collaborations across the University of Florida (UF) Colleges, Centers and Institutes and will capitalize on the existing strengths of the Institute on Aging/Pepper Center Cores in clinical and basic research, of the McKnight Brain Institute, of the Departments of Neurology, Neuroscience, Psychiatry and Aging and Geriatric Research, and of the extremely rich UF grant funding portfolio in the arena of aging, brain, cognition and memory; will participate in maximizing the success in extramural funding of the Program; will assist with leading interdisciplinary programmatic grants; will function as a mentor for junior faculty members and trainees; in concert with the other key stakeholders, will assist with the planning, coordination and implementation of the research goals of the Program. There will be a possibility to perform clinical work in the appropriate specialty.

RESOURCES

A generous development package is available through the endowed fund of the McKnight Brain Research Foundation and the UF, which includes resources for salary, faculty, staff, trainees, equipment and other development costs. Prime office and research space is available through the Institute on Aging.

The Best Care - The Best Career

Veterans Affairs Medical Center San Francisco



Full-time Psychiatrist

VA Clearlake Community Based Outpatient Clinic

The Mental Health Service at the San Francisco Veterans Administration Medical Center is seeking a board certified or eligible psychiatrist to join the staff of the new Clearlake, CA clinic targeted to open October 2010. Clearlake is a charming lake resort community located in beautiful Northern California just two hours by car from the San Francisco bay area, the Sacramento valley, or the Pacific Coast. The initial mental health staffing will be a psychiatrist and a licensed social worker. The clinical responsibilities will emphasize psychopharmacologic therapies, but also include psychiatric evaluations and consultations. There are excellent health and retirement benefits, recruitment incentive and paid time off package. Salary is competitive and negotiable depending on qualifications. The selected applicant may be subject to random pre-employment drug screening. U.S. citizenship required. Interested applicants please send CV to Linda Nestor, Human Resources Specialist, at linda.nestor@va.gov.


Full-time Psychiatrist

VA Santa Rosa Community Based Outpatient Clinic

The Mental Health Service at the San Francisco Veterans Administration Medical Center is seeking a board certified or eligible psychiatrist to join the staff of the Santa Rosa Community Based Outpatient Clinic (CBOC). The Santa Rosa CBOC has well-established multidisciplinary mental health services with a staff of eight clinicians including four psychiatrists. The Santa Rosa CBOC has just relocated to a new facility which allows for an extended range of services to veterans in the Santa Rosa area. Mental Health services work closely with the Primary Care at the Clinic and are developing an integrated Primary Care/Mental Health model of care. The clinical responsibilities of this position will emphasize psychopharmacologic therapies, but, also includes psychiatric evaluations and consultations. There are opportunities to teach and receive a Clinical Faculty appointment with the University of California, School of Medicine, San Francisco. There are excellent health and retirement benefits, recruitment incentive and paid time off package. Salary is competitive and negotiable depending on qualifications. The selected applicant may be subject to random pre-employment drug screening. U.S. citizenship required. Interested applicants please send CV to Summer Ezzat, Human Resources Specialist, at summer.ezzat.va.gov

THE DEPARTMENT OF VETERANS AFFAIRS IS AN EQUAL OPPORTUNITY EMPLOYER

Treat correctional patients more effectively with these new resources!



Handbook of Correctional Mental Health, Second Edition

Edited by Charles L. Scott, M.D.

This book addresses key concepts to ensure that the reader meets the current standard of care for inmates through all phases of the criminal justice system. In 20 state-of-the-art chapters, nationally recognized providers and correctional mental health experts address the most pressing issues facing clinicians.

2010 • 720 pages • ISBN 978-1-58562-389-1 Paperback
\$77.00 • Item #62389

Manual of Forms and Guidelines for Correctional Mental Health

CD ROM included!

Edited by Amanda Ruiz, M.D., Joel A. Dvoskin, Ph.D., Charles L. Scott, M.D., and Jeffrey L. Metzner, M.D., P.C.

This compendium of forms, guidelines, and procedures for use in clinical correctional mental health settings has been specifically designed to provide guidance in documentation and procedures for administrators, clinicians, and correctional officers.

2010 • 256 pages • ISBN 978-1-58562-361-7 • Paperback • \$115.00 • Item #62361

Set Price: \$163.00 • Item #5101

The First and Last Word in Psychiatry



Order online: www.appi.org

Phone: 703-907-7322 or 1-800-368-5777 (Mon.-Fri., 9 am to 5:30 pm, ET)

Fax: 703-907-1091 | Email: appi@psych.org

Priority code: AH1010AA

Volunteer for DSM-5 Field Trials

American Psychiatric Institute for Research and Education
Practice Research Network is recruiting

Practicing Psychiatrists

As the 2013 date for publication of the fifth edition of *Diagnostic and Statistical Manual of Mental Disorders* (DSM-5) draws near, the research and clinical experts working on DSM-5 will be finalizing the diagnostic criteria and testing potential revisions and assessment tools in field trials across a number of clinical settings.

The DSM-5 Field Trials involving practicing psychiatrists will focus primarily on 1) the feasibility and clinical utility of the proposed modifications to the diagnostic criteria for a broad range of disorders in the full range of clinical settings, and 2) the feasibility and clinical utility of cross-cutting and diagnostic-specific dimensional measures that are incorporated into the diagnostic scheme for DSM-5.

Practicing psychiatrists interested in volunteering for potential participation in DSM-5 field trials should send an email to aparesearch@psych.org with the following information:

- Full name
- Institution or organizational affiliation
- Mailing address
- Job title
- Preferred e-mail
- Area of expertise (e.g., child psychiatry, geriatric psychiatry, etc.)

This information will help determine your eligibility to participate in the DSM-5 field trials.

For information about revisions to the DSM
please visit www.DSM5.org

The American Psychiatric Institute for Research and Education is a 501 (c) (3) subsidiary of the American Psychiatric Association.



Psychiatrist Opportunities

STG International, a government contractor with more than 1,000 healthcare professionals in 41 states, is a national leader in the provision of medical staff and support services. We work in a variety of inpatient and outpatient settings including behavioral, mental, occupational and correctional health.

- We believe in accountability, at every level, at every turn, so that each of us stays connected to the greater pursuit.
- With urgency and resolve, we seek our objectives. For good, not for glory.
- Building a country, piece by piece, that's stronger than it was, safer than it was, more effective, more productive.
- It's possible, because we make it possible.



Great benefits! Competitive compensation!

STG International has immediate full-time civilian opportunities for Psychiatrists MD/DO at the following Department of Immigration Health Services detention facilities:

- Jena, LA
- Florence, AZ
- Lumpkin, GA
- El Centro, Ca
- San Diego, CA
- El Paso, TX
- Pearsall, TX
- Raymondville, TX

Eligible Psychiatrists must be Board Certified or Board Eligible, US citizen, and be able to pass a security clearance and have the appropriate state specific license. Interested candidates please apply online at our website

www.stginternational.com/careers
or send a current CV to acooper@stginternational.com
or smcneil@stginternational.com

STG is an EOE

Psychiatrist

Amery, Wisconsin



HealthPartners has an exciting opportunity for a practicing psychiatrist to join our group at the Amery Regional Medical Center (ARMC) in Amery, WI.

This key position will provide direct patient care as chief physician for our psychiatric treatment program, coordinate ARMC's psychiatric medical policies and procedures, and implement appropriate integration of clinical and medical services.

Top candidates will be board certified by the American Board of Psychiatry and Neurology or the Osteopathic Board of Neurology and Psychiatry. Geriatrics experience or board eligibility in geropsychiatry is preferred.

Forward CV and cover letter to lori.m.fake@healthpartners.com or apply online at www.healthpartners.jobs. For more details, call (800) 472-4695 x1. EOE

 **HealthPartners**
Medical Group

www.healthpartners.com

Index to Advertisers July 2010

The publication of an advertisement in this journal does not imply endorsement of the product or service by the American Psychiatric Association.

Sepracor, Inc.

Lurasidone C2-A1

Employment Opportunities A20-A23

American Journal of Psychotherapy.....A13

U.S. Pharmaceuticals, Pfizer, Inc.

Pristiq A24-C4

Subscription and Business Information

The American Journal of Psychiatry, ISSN 0002-953X, is published monthly by the American Psychiatric Association, 1000 Wilson Blvd., Suite 1825, Arlington, VA 22209-3901. Subscriptions (per year): individual \$230.00, international \$347.00. For additional subscription options, including single issues and student rates, please contact Customer Service at 1-800-368-5777 or email appi@psych.org. Institutional subscriptions are tier priced. For institutional site license or pricing information, contact 703-907-8538 or email institutions@psych.org.

Business communications, address changes, and subscription questions from APA members should be directed to the Division of Member Services: (888) 35-PSYCH (toll-free). Nonmember subscribers should call the Circulation Department (800) 368-5777. Author inquiries should be directed to the Journal editorial office: (703) 907-7885 or (703) 907-7884; fax (703) 907-1096; e-mail ajp@psych.org.

Business Management: Nancy Frey, Director, Publishing Services; Laura G. Abedi, Associate Director, Production; Alison Jones, Advertising Prepress Manager; Robert Pursell, Associate Publisher Advertising, Sales and Marketing.

Pharmaceutical Print Advertising: Frank Cox, Kathleen Harrison, Valentin Torres, Pharmaceutical Media, Inc. 30 East 33rd Street, New York, NY 10016. (212) 685-5010; fax (212) 685-6126; e-mail vtorres@pminy.com.

Nonpharmaceutical and Online Sales: Brian Skepton, (703) 907-7332; e-mail bskepton@psych.org.

Pages are produced using Adobe InDesign CS4. Printed by RR Donnelley, Mendota, IL, on acid-free paper effective with Volume 164, Number 11, November 2007.

Periodicals postage paid at Arlington, VA, and additional mailing offices. POSTMASTER: Send address changes to The American Journal of Psychiatry, Circulation Department, American Psychiatric Association, 1000 Wilson Blvd., Suite 1825, Arlington, VA 22209-3901.

Indexed in Abstracts for Social Workers, Academic Abstracts, Biological Abstracts, Chemical Abstracts, Chicago Psychoanalytic Literature Index, Cumulative Index to Nursing Literature, Excerpta Medica, Hospital Literature Index, Index Medicus, International Nursing Index, Nutrition Abstracts, Psychological Abstracts, Science Citation Index, Social Science Source, and Social Sciences Index.

The American Psychiatric Association does not hold itself responsible for statements made in its publications by contributors or advertisers. Unless so stated, material in The American Journal of Psychiatry does not reflect the endorsement, official attitude, or position of the American Psychiatric Association or of the Journal's Editorial Board.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by the American Psychiatric Association for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of \$15.00 per copy is paid directly to CCC, 222 Rosewood Drive, Danvers, MA 01923; (978) 750-8400 (tel), (978) 646-8600 (fax), www.copyright.com (web site). 0002-953X/05/\$15.00.

This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Requests for commercial distribution should be directed to (703) 907-7894. APA does not require that permission be obtained for the photocopying of isolated articles for nonprofit classroom or library reserve use; all fees associated with such permission are waived.

Copyright © 2010 American Psychiatric Association.



Extended-Release Tablets

BRIEF SUMMARY. See package insert for full Prescribing Information. For further product information and current package insert, please visit www.wyeth.com or call our medical communications department toll-free at 1-800-934-5556.

WARNING: Suicidality and Antidepressant Drugs

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Pristiq or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Pristiq is not approved for use in pediatric patients [see Warnings and Precautions (5.1), Use in Specific Populations (8.4), and Patient Counseling Information (17.1) in the full prescribing information].

INDICATIONS AND USAGE: Pristiq, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is indicated for the treatment of major depressive disorder (MDD).

CONTRAINDICATIONS: Hypersensitivity-Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the Pristiq formulation. **Monoamine Oxidase Inhibitors**-Pristiq must not be used concomitantly in patients taking monoamine oxidase inhibitors (MAOIs) or in patients who have taken MAOIs within the preceding 14 days due to the risk of serious, sometimes fatal, drug interactions with SNRI or SSRI treatment or with other serotonergic drugs. Based on the half-life of desvenlafaxine, at least 7 days should be allowed after stopping Pristiq before starting an MAOI [see Dosage and Administration (2.5) in the full prescribing information].

WARNINGS AND PRECAUTIONS: Clinical Worsening and Suicide Risk-Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older. The pooled analyses of placebo-controlled studies in children and adolescents with MDD, obsessive-compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term studies of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled studies in adults with MDD or other psychiatric disorders included a total of 295 short-term studies (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1,000 patients treated) are provided in Table 1 of the full prescribing information. No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about drug effect on suicide. It is unknown whether the suicidality risk extends to longer-term use, ie, beyond several months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with depression that the use of antidepressants can delay the recurrence of depression. **All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.** The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms [see Warnings and Precautions (5.9) and Dosage and Administration (2.3) in the full prescribing information for a description of the risks of discontinuation of Pristiq]. Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for Pristiq should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose. **Screening patients for bipolar disorder**-A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled studies) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that Pristiq is not approved for use in treating bipolar depression. **Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions**-The development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including Pristiq treatment, but particularly with concomitant use of serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. Serotonin syndrome symptoms may include mental status changes (eg, agitation, hallucinations, coma), autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (eg, hyperreflexia, incoordination) and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea). Serotonin syndrome in its most severe form can resemble neuroleptic malignant syndrome, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes. Patients should be monitored for the emergence of serotonin syndrome or NMS-like signs and symptoms. The concomitant use of Pristiq with MAOIs intended to treat depression is contraindicated [see Contraindications (4.2)]. If concomitant treatment of Pristiq with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. The concomitant use of Pristiq with serotonergic agents (such as tryptophan) is not recommended. Treatment with Pristiq and any concomitant serotonergic or antiparkinsonian agents, including antipsychotics, should be discontinued immediately if the above events occur, and supportive symptomatic treatment should be initiated. **Elevated Blood Pressure**-Patients receiving Pristiq should have regular monitoring of blood pressure since dose-dependent increases were observed in clinical studies. Pre-existing hypertension should be controlled before initiating treatment with Pristiq. Caution should be exercised in treating patients with pre-existing hypertension or other underlying conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported with Pristiq. **Sustained hypertension**-Sustained blood pressure increases could have adverse consequences. For patients who experience a sustained increase in blood pressure while receiving Pristiq, either dose reduction or discontinuation should be considered [see Adverse Reactions (6.1)]. Treatment with Pristiq in controlled studies was associated with sustained hypertension, defined as treatment-emergent supine diastolic blood pressure (SDBP) ≥ 90 mm Hg and ≥ 10 mm Hg above baseline for 3 consecutive on-therapy visits. In clinical studies, regarding the proportion of patients with sustained hypertension, the following rates were observed: placebo (0.5%), Pristiq 50 mg (1.3%), Pristiq 100 mg (0.7%), Pristiq 200 mg (1.1%), and Pristiq 400 mg (2.3%). Analyses of patients in Pristiq controlled studies who met criteria for sustained hypertension revealed a

dose-dependent increase in the proportion of patients who developed sustained hypertension. **Abnormal Bleeding**-SSRIs and SNRIs can increase the risk of bleeding events. Concomitant use of aspirin, other drugs that affect platelet function, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants can add to this risk. Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages. Patients should be cautioned about the risk of bleeding associated with the concomitant use of Pristiq and NSAIDs, aspirin, or other drugs that affect coagulation or bleeding. **Narrow-angle Glaucoma**-Mydriasis has been reported in association with Pristiq; therefore, patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma (angle-closure glaucoma) should be monitored. **Activation of Mania/Hypomania**-During all MDD and VMS (vasomotor symptoms) phase 2 and phase 3 studies, mania was reported for approximately 0.1% of patients treated with Pristiq. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorder who were treated with other marketed antidepressants. As with all antidepressants, Pristiq should be used cautiously in patients with a history or family history of mania or hypomania. **Cardiovascular/Cerebrovascular Disease**-Caution is advised in administering Pristiq to patients with cardiovascular, cerebrovascular, or lipid metabolism disorders [see *Adverse Reactions* (6.1)]. Increases in blood pressure and heart rate were observed in clinical studies with Pristiq. Pristiq has not been evaluated systematically in patients with a recent history of myocardial infarction, unstable heart disease, uncontrolled hypertension, or cerebrovascular disease. Patients with these diagnoses, except for cerebrovascular disease, were excluded from clinical studies. **Serum Cholesterol and Triglyceride Elevation**-Dose-related elevations in fasting serum total cholesterol, LDL (low-density lipoprotein) cholesterol, and triglycerides were observed in the controlled studies. Measurement of serum lipids should be considered during treatment with Pristiq [see *Adverse Reactions* (6.1)]. **Discontinuation of Treatment with Pristiq**-Discontinuation symptoms have been systematically and prospectively evaluated in patients treated with Pristiq during clinical studies in major depressive disorder. Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis. In general, discontinuation events occurred more frequently with longer duration of therapy. During marketing of SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors) and SSRIs (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, paresthesia, such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. Patients should be monitored for these symptoms when discontinuing treatment with Pristiq. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate [see *Dosage and Administration* (2.4) and *Adverse Reactions* (6.1) in full prescribing information]. **Renal Impairment**-In patients with moderate or severe renal impairment or end-stage renal disease (ESRD) the clearance of Pristiq was decreased, thus prolonging the elimination half-life of the drug. As a result, there were potentially clinically significant increases in exposures to Pristiq [see *Clinical Pharmacology* (12.6) in full prescribing information]. Dosage adjustment (50 mg every other day) is necessary in patients with severe renal impairment or ESRD. The doses should not be escalated in patients with moderate or severe renal impairment or ESRD [see *Dosage and Administration* (2.2) in full prescribing information]. **Seizure**-Cases of seizure have been reported in premarketing clinical studies with Pristiq. Pristiq should be prescribed with caution in patients with a seizure disorder. **Hypotension**-Hypotension can occur as a result of treatment with SSRIs and SNRIs, including Pristiq. In many cases, this hypotension appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Elderly patients who are at greater risk of developing hypotension with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see *Use in Specific Populations* (8.5) and *Clinical Pharmacology* (12.6) in full prescribing information]. Discontinuation of Pristiq should be considered in patients with symptomatic hypotension and appropriate medical intervention should be instituted. **Coadministration of Drugs Containing Desvenlafaxine and Venlafaxine**-Desvenlafaxine is the major active metabolite of venlafaxine. Products containing desvenlafaxine and products containing venlafaxine should not be used concomitantly with Pristiq. **Interstitial Lung Disease and Eosinophilic Pneumonia**-Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of Pristiq) therapy have been rarely reported. The possibility of these adverse events should be considered in patients treated with Pristiq who present with progressive dyspnea, cough, or chest discomfort. Such patients should undergo a prompt medical evaluation, and discontinuation of Pristiq should be considered.

ADVERSE REACTIONS: Clinical Studies Experience: The most commonly observed adverse reactions in Pristiq-treated MDD patients in short-term fixed-dose studies (incidence $\geq 5\%$ and at least twice the rate of placebo in the 50- or 100-mg dose groups) were nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders. **Adverse reactions reported as reasons for discontinuation of treatment:** The most common adverse reactions leading to discontinuation in at least 2% of the Pristiq-treated patients in the short-term studies, up to 8 weeks, were nausea (4%); dizziness, headache and vomiting (2% each); in the long-term study, up to 9 months, the most common was vomiting (2%). **Common adverse reactions in placebo-controlled MDD studies:** Table 3 in full PI shows the incidence of common adverse reactions that occurred in $\geq 2\%$ of Pristiq-treated MDD patients at any dose in the 8-week, placebo-controlled, fixed-dose, premarketing clinical studies. In general, the adverse reactions were most frequent in the first week of treatment. **Cardiac disorders:** Palpitations, Tachycardia, Blood pressure increased; **Gastrointestinal disorders:** Nausea, Dry mouth, Diarrhea, Constipation, Vomiting; **General disorders and administration site conditions:** Fatigue, Chills, Feeling jittery, Asthenia; **Metabolism and nutrition disorders:** Decreased appetite, weight decreased; **Nervous system disorders:** Dizziness, Somnolence, Headache, Tremor, Paraesthesia, Disturbance in attention; **Psychiatric disorders:** Insomnia, Anxiety, Nervousness, Irritability, Abnormal dreams; **Renal and urinary disorders:** Urinary hesitation; **Respiratory, thoracic, and mediastinal disorders:** Yawning; **Skin and subcutaneous tissue disorders:** Hyperhidrosis, Rash; **Special Senses:** Vision blurred; **Mydriasis, Tinnitus, Dysgeusia;** **Vascular Disorders:** Hot flush. **Sexual function adverse reactions:** Table 4 shows the incidence of sexual function adverse reactions that occurred in $\geq 2\%$ of Pristiq-treated MDD patients in any fixed-dose group (8-week, placebo-controlled, fixed and flexible-dose, premarketing clinical studies). **Men Only:** Anorgasmia, Libido decreased, Orgasm abnormal, Ejaculation delayed, Erectile dysfunction, Ejaculation disorder, Ejaculation failure, Sexual dysfunction; **Women Only:** Anorgasmia; **Other adverse reactions observed in premarketing clinical studies:** Other infrequent adverse reactions occurring at an incidence of $< 2\%$ in MDD patients treated with Pristiq were: **Immune system disorders** - Hypersensitivity. **Investigations** - Weight increased, liver function test abnormal, blood prolactin increased. **Nervous system disorders** - Convulsion, syncope, extrapyramidal disorder. **Musculoskeletal and connective tissue disorders** - Musculoskeletal stiffness. **Psychiatric disorders** - Depersonalization, hypomania. **Respiratory, thoracic and mediastinal disorders** - Epistaxis. **Vascular disorders** - Orthostatic hypotension. In clinical studies, there were uncommon reports of ischemic cardiac adverse events, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors. More patients experienced these events during Pristiq treatment as compared to placebo [see *Warnings and Precautions* (5.7)]. **Discontinuation events**-Adverse events reported in association with abrupt discontinuation, dose reduction or tapering of treatment in MDD clinical studies at a rate of $\geq 5\%$ include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, abnormal dreams, fatigue, and hyperhidrosis. In general, discontinuation events occurred more frequently with longer duration of therapy [see *Dosage and Administration* (2.4) and *Warnings and Precautions* (5.9) in full prescribing information]. **Laboratory, ECG and vital sign changes observed in MDD clinical studies:** The following changes were observed in placebo-controlled, short-term, premarketing MDD studies with Pristiq. **Lipids**-Elevations in fasting serum total cholesterol, LDL (low-density lipoprotein) cholesterol, and triglycerides occurred in the controlled studies. Some of these abnormalities were considered potentially clinically significant [see *Warnings and Precautions* (5.8)]. **Proteinuria**-Proteinuria, greater than or equal to trace, was observed in the fixed-dose controlled studies (see Table 6 in full prescribing information). This proteinuria was not associated with increases in BUN or creatinine and was generally transient. **ECG changes**-Electrocardiograms were obtained from 1,492 Pristiq-treated patients with major depressive disorder and 984 placebo-treated patients in clinical studies lasting up to 8 weeks. No clinically relevant differences were observed between Pristiq-treated and placebo-treated patients for QT, QTc, PR, and QRS intervals. In a thorough QTc study with prospectively determined criteria, desvenlafaxine did not cause QT prolongation. No difference was observed between placebo and desvenlafaxine treatments for the QRS interval. **Vital sign changes**-Table 7 summarizes the changes that were observed in placebo-controlled, short-term, premarketing studies with Pristiq in patients with MDD (doses 50 to 400 mg). Relative to placebo, Pristiq was associated with mean increase of up to 2.1 mm Hg in systolic blood pressure, 2.3 mm Hg in diastolic blood pressure, and 4.1 bpm with supine pulse. At the final on-therapy assessment in the 6-month, double-blind, placebo-controlled phase of a long-term study in patients who had responded to Pristiq during the initial 12-week, open-label phase, there was no statistical difference in mean weight gain between Pristiq- and placebo-treated patients. **Orthostatic hypotension**-In the short-term, placebo-controlled clinical studies with doses of 50-400 mg, systolic orthostatic hypotension (decrease ≥ 30 mm Hg from supine to standing position) occurred more frequently in patients ≥ 65 years of age receiving Pristiq (8.0%, 7/87) versus placebo (2.5%, 1/40), compared to patients < 65 years of age receiving Pristiq (0.9%, 18/1,937) versus placebo (0.7%, 8/1,218). **Adverse Reactions Identified During Post-Approval Use**-The following adverse reaction has been identified during post-approval use of Pristiq. Because post-approval reactions are reported

voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. *Skin and subcutaneous tissue disorders* - Angioedema. **DRUG INTERACTIONS: Central Nervous System (CNS)-Active Agents**-The risk of using Pristiq in combination with other CNS-active drugs has not been systematically evaluated. Consequently, caution is advised when Pristiq is taken in combination with other CNS-active drugs [see *Warnings and Precautions* (5.13)]. **Monamine Oxidase Inhibitors (MAOIs)**-Adverse reactions, some of which were serious, have been reported in patients who have recently been discontinued from a monoamine oxidase inhibitor (MAOI) and started on antidepressants with pharmacological properties similar to Pristiq (SNRIs or SSRIs), or who have recently had SNRI or SSRI therapy discontinued prior to initiation of an MAOI [see *Contraindications* (4.2)]. **Serotonergic Drugs**-Based on the mechanism of action of Pristiq and the potential for serotonin syndrome, caution is advised when Pristiq is coadministered with other drugs that may affect the serotonergic neurotransmitter systems [see *Warnings and Precautions* (5.2)]. **Drugs that Interfere with Hemostasis (eg, NSAIDs, Aspirin, and Warfarin)**-Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of case-control and cohort design have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding. These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are coadministered with warfarin. Patients receiving warfarin therapy should be carefully monitored when Pristiq is initiated or discontinued. **Ethanol**-A clinical study has shown that desvenlafaxine does not increase the impairment of mental and motor skills caused by ethanol. However, as with all CNS-active drugs, patients should be advised to avoid alcohol consumption while taking Pristiq. **Potential for Other Drugs to Affect Desvenlafaxine-Inhibitors of CYP3A4 (ketoconazole)**-CYP3A4 is a minor pathway for the metabolism of Pristiq. Concomitant use of Pristiq with potent inhibitors of CYP3A4 may result in higher concentrations of Pristiq. **Inhibitors of other CYP enzymes**-Based on *in vitro* data, drugs that inhibit CYP isozymes 1A1, 1A2, 2A6, 2D6, 2C8, 2C9, 2C19, and 2E1 are not expected to have significant impact on the pharmacokinetic profile of Pristiq. **Potential for Desvenlafaxine to Affect Other Drugs- Drugs metabolized by CYP2D6 (desipramine)**-*In vitro* studies showed minimal inhibitory effect of desvenlafaxine on CYP2D6. Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily. Concomitant use of desvenlafaxine with a drug metabolized by CYP2D6 can result in higher concentrations of that drug. **Drugs metabolized by CYP3A4 (midazolam)**-*In vitro*, desvenlafaxine does not inhibit or induce the CYP3A4 isozyme. Concomitant use of Pristiq with a drug metabolized by CYP3A4 can result in lower exposures to that drug. **Drugs metabolized by CYP1A2, 2A6, 2C8, 2C9, and 2C19**-*In vitro*, desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19 isozymes and would not be expected to affect the pharmacokinetics of drugs that are metabolized by these CYP isozymes. **P-glycoprotein Transporter**-*In vitro*, desvenlafaxine is not a substrate or an inhibitor for the P-glycoprotein transporter. The pharmacokinetics of Pristiq are unlikely to be affected by drugs that inhibit the P-glycoprotein transporter, and desvenlafaxine is not likely to affect the pharmacokinetics of drugs that are substrates of the P-glycoprotein transporter. **Electroconvulsive Therapy**-There are no clinical data establishing the risks and/or benefits of electroconvulsive therapy combined with Pristiq treatment. **USE IN SPECIFIC POPULATIONS: Pregnancy**-Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy. **Teratogenic effects**-**Pregnancy Category C**: There are no adequate and well-controlled studies of Pristiq in pregnant women. Therefore, Pristiq should be used during pregnancy only if the potential benefits justify the potential risks. **Non-teratogenic effects**-Neonates exposed to SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), or SSRIs (Selective Serotonin Reuptake Inhibitors), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome [see *Warnings and Precautions* (5.2)]. When treating a pregnant woman with Pristiq during the third trimester, the physician should carefully consider the potential risks and benefits of treatment [see *Dosage and Administration* (2.2)]. **Labor and Delivery**-The effect of Pristiq on labor and delivery in humans is unknown. Pristiq should be used during labor and delivery only if the potential benefits justify the potential risks. **Nursing Mothers**-Desvenlafaxine (O-desmethylvenlafaxine) is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from Pristiq, a decision should be made whether or not to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Only administer Pristiq to breastfeeding women if the expected benefits outweigh any possible risk. **Pediatric Use**-Safety and effectiveness in the pediatric population have not been established [see *Box Warning and Warnings and Precautions* (5.1)]. Anyone considering the use of Pristiq in a child or adolescent must balance the potential risks with the clinical need. **Geriatric Use**-Of the 3,292 patients in clinical studies with Pristiq, 5% were 65 years of age or older. No overall differences in safety or efficacy were observed between these patients and younger patients; however, in the short-term, placebo-controlled studies, there was a higher incidence of systolic orthostatic hypotension in patients ≥ 65 years of age compared to patients < 65 years of age treated with Pristiq [see *Adverse Reactions* (6)]. For elderly patients, possible reduced renal clearance of desvenlafaxine should be considered when determining dose [see *Dosage and Administration* (2.2) and *Clinical Pharmacology* (12.6)]. If Pristiq is poorly tolerated, every other day dosing can be considered. SSRIs and SNRIs, including Pristiq, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see *Warnings and Precautions* (5.12)]. Greater sensitivity of some older individuals cannot be ruled out. **Renal Impairment**-In subjects with renal impairment the clearance of Pristiq was decreased. In subjects with severe renal impairment (24-hr CrCl < 30 mL/min) and end-stage renal disease, elimination half-lives were significantly prolonged, increasing exposures to Pristiq; therefore, dosage adjustment is recommended in these patients [see *Dosage and Administration* (2.2) and *Clinical Pharmacology* (12.6) in full prescribing information]. **Hepatic Impairment**-The mean $t_{1/2}$ changed from approximately 10 hours in healthy subjects and subjects with mild hepatic impairment to 13 and 14 hours in moderate and severe hepatic impairment, respectively. The recommended dose in patients with hepatic impairment is 50 mg/day. Dose escalation above 100 mg/day is not recommended [see *Clinical Pharmacology* (12.6)].

OVERDOSAGE: Human Experience with Overdosage-There is limited clinical experience with desvenlafaxine succinate overdosage in humans. In premarketing clinical studies, no cases of fatal acute overdose of desvenlafaxine were reported. The adverse reactions reported within 5 days of an overdose > 600 mg that were possibly related to Pristiq included headache, vomiting, agitation, dizziness, nausea, constipation, diarrhea, dry mouth, paresthesia, and tachycardia. Desvenlafaxine (Pristiq) is the major active metabolite of venlafaxine. Overdose experience reported with venlafaxine (the parent drug of Pristiq) is presented below; the identical information can be found in the *Overdosage* section of the venlafaxine package insert. In postmarketing experience, overdose with venlafaxine (the parent drug of Pristiq) has occurred predominantly in combination with alcohol and/or other drugs. The most commonly reported events in overdose include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, seizures, and vomiting. Electrocardiogram changes (eg, prolongation of QT interval, bundle branch block, QRS prolongation), sinus and ventricular tachycardia, bradycardia, hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin syndrome, and death have been reported. Published retrospective studies report that venlafaxine overdose may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher pre-existing burden of suicide risk factors than SSRI-treated patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdose, as opposed to some characteristic(s) of venlafaxine-treated patients, is not clear. Prescriptions for Pristiq should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose. **Management of Overdosage**-Treatment should consist of those general measures employed in the management of overdose with any SSRI/SNRI. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal should be administered. Induction of emesis is not recommended. Because of the moderate volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for desvenlafaxine are known. In managing an overdose, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose. Telephone numbers for certified poison control centers are listed in the Physicians Desk Reference (PDR).

This brief summary is based on Pristiq Prescribing Information W10529C009, revised September 2009.

FOR MAJOR DEPRESSIVE DISORDER


Help your patients

on a path forward with proven SNRI therapy

It's not just about starting your adult patients with MDD on therapy; it's about helping them toward their treatment goals. Patients should be periodically reassessed to determine the need for continued treatment.¹

PRISTIQ 50 mg:

- SNRI therapy with efficacy proven in 8-week clinical studies
- Discontinuation rate due to adverse events comparable to placebo in 8-week clinical studies
- One recommended therapeutic dose from the start¹



Important Treatment Considerations for PRISTIQ

PRISTIQ is indicated for the treatment of major depressive disorder in adults.

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of PRISTIQ or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. PRISTIQ is not approved for use in pediatric patients.

Contraindications

- PRISTIQ is contraindicated in patients with a known hypersensitivity to PRISTIQ or venlafaxine.
- PRISTIQ must not be used concomitantly with an MAOI or within 14 days of stopping an MAOI. Allow 7 days after stopping PRISTIQ before starting an MAOI.

Warnings and Precautions

- All patients treated with antidepressants should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of treatment and when changing the dose. Consider changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or includes symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania, or suicidality that are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Families and caregivers of patients being treated with antidepressants should be alerted about the need to monitor patients.
- Development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome-like reactions have been reported with SNRIs and SSRIs alone, including PRISTIQ treatment, but particularly with concomitant use of serotonergic drugs, including triptans, with drugs that impair the metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. If concomitant use with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Concomitant use of PRISTIQ with serotonin precursors is not recommended.
- Patients receiving PRISTIQ should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies. Pre-existing hypertension should be controlled before starting PRISTIQ. Caution should be exercised in treating patients with pre-existing hypertension or other underlying conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported. For patients who experience a sustained increase in blood pressure, either dose reduction or discontinuation should be considered.

- SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events. Concomitant use of aspirin, NSAIDs, warfarin, and other anticoagulants may add to this risk.
- Mydriasis has been reported in association with PRISTIQ; therefore, patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma (angle-closure glaucoma) should be monitored.
- PRISTIQ is not approved for use in bipolar depression. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine the risk of bipolar disorder.
- As with all antidepressants, PRISTIQ should be used cautiously in patients with a history or family history of mania or hypomania, or with a history of seizure disorder.
- Caution is advised in administering PRISTIQ to patients with cardiovascular, cerebrovascular, or lipid metabolism disorders. Increases in blood pressure and small increases in heart rate were observed in clinical studies with PRISTIQ. PRISTIQ has not been evaluated systematically in patients with a recent history of myocardial infarction, unstable heart disease, uncontrolled hypertension, or cerebrovascular disease.
- Dose-related elevations in fasting serum total cholesterol, LDL (low density lipoprotein) cholesterol, and triglycerides were observed in clinical studies. Measurement of serum lipids should be considered during PRISTIQ treatment.
- On discontinuation, adverse events, some of which may be serious, have been reported with PRISTIQ and other SSRIs and SNRIs. Abrupt discontinuation of PRISTIQ has been associated with the appearance of new symptoms. Patients should be monitored for symptoms when discontinuing treatment. A gradual reduction in dose rather than abrupt cessation is recommended whenever possible.
- The recommended dose in patients with severe renal impairment or end-stage renal disease (ESRD) is 50 mg every other day. The dose should not be escalated in patients with moderate or severe renal impairment or ESRD.
- Products containing desvenlafaxine and products containing venlafaxine should not be used concomitantly with PRISTIQ.
- Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. Discontinuation of PRISTIQ should be considered in patients with symptomatic hyponatremia.
- Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported.

Adverse Reactions

- The most commonly observed adverse reactions in patients taking PRISTIQ vs placebo for MDD in short-term fixed-dose premarketing studies (incidence $\geq 5\%$ and $\geq 2\times$ the rate of placebo in the 50-mg dose group) were nausea (22% vs 10%), dizziness (13% vs 5%), hyperhidrosis (10% vs 4%), constipation (9% vs 4%), and decreased appetite (5% vs 2%).

Reference: 1. Pristiq® (desvenlafaxine) Prescribing Information, Wyeth Pharmaceuticals Inc.

Please see brief summary of Prescribing Information on adjacent pages.

For more information on PRISTIQ, please visit www.PristiqHCP.com.

Pristiq[®]
EXTENDED-RELEASE TABLETS



261838-01 © 2009 Pfizer Inc.
All rights reserved. December 2009